OncoMatch/Clinical Trials/NCT06730295

Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer

Is NCT06730295 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for lung cancer (nsclc).

Phase 2RecruitingSun Yat-sen UniversityNCT06730295Data as of May 2026

This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with centrally located early-stage non-small cell lung cancer (NSCLC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage T1-2N0M0, RT1-2N0M0

untreated early-stage non-small cell lung cancer (T1-2N0M0), or recurrent disease (rT1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Lab requirements

Blood counts

serum hemoglobin ≥ 80 g/l, platelets ≥ 100,000/μl, absolute neutrophil count ≥ 1,500/μl

Kidney function

serum creatinine ≤ 1.25 times the upper normal limit (unl) or creatinine clearance ≥ 60 ml/min

Liver function

serum bilirubin ≤ 1.5 times unl, ast (sgot) and alt (sgpt) ≤ 2.5 times unl, alkaline phosphatase ≤ 5 times unl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify